CClinicalTrials.gg
CompletedNCT06251427Updated Jul 28, 2025

Assessing the Effectiveness of a Multiple-micronutrient Fortified Maize Pap on the Nutrient Status of Nigerian School-aged Children

An interventional study of Multiple micronutrient fortified maize with milk in Iron Deficiencies, sponsored by FrieslandCampina. Completed at 1 site in Netherlands. Open to participants aged 5 Years to 8 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-28.

Sponsored by FrieslandCampina · Not applicable, Interventional, and Prevention

Phase
Not applicable
Study type
Interventional
Enrollment
934
Allocation
Randomized
Ages
5 Years to 8 Years
Sex
All
01

Study summary

A new product was developed by FrieslandCampina for Sub-Saharan Africa as affordable nutrition to nourish Nigerian families of low to middle-socioeconomic class (SEC). It can potentially be used to enhance the ongoing school feeding programs, which are aimed at reducing malnutrition, including micronutrient deficiencies. The main component of the product is maize, which is a traditional staple in Nigeria. The product also contains milk (being a good source of high quality protein) fortified with various micronutrients including iron, iodine, zinc, vitamin A and vitamin B12 at levels contributing to approximately 1/3 of daily recommended intakes per serving of product. Intake of this product may therefore contribute to improvement of micronutrient status among Nigerian schoolchildren suffering from such nutrient deficiencies. Micronutrients are important for various processes in the body, which in turn may influence other outcomes as cognitive performance, reduce illness and improve growth.

Read the detailed description

The study is a double-blinded three-arm intervention trial. The individual children will be randomised into the three different arms of the study, with varying doses of micronutrients (1) low, (2) medium and (3) high.

The 50g of study product will be given to school children every school day (5/7 days of the week) for 5 intervention months.

Study product: A fermented maize pap, with soy, dairy and multiple micronutrient fortification. Active components: Multiple micronutrient fortification, including ferrous fumarate. Amount of micronutrients differ based on the arm of the study.

02

Conditions studied

  • Iron Deficiencies

Browse trials for

Keywords

  • School-aged children
  • Nigeria
  • Multiple-micronutrient fortification
  • School feeding program
03

In context

Iron Deficiencies

772 studies on the registry are indexed under Iron Deficiencies; 115 are open to participants now.

This study's enrollment of 934 is above the median of 100 across 592 interventional studies indexed under Iron Deficiencies.

Browse Iron Deficiencies studies →

Lead sponsor

FrieslandCampina is the lead sponsor of 11 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years to 8 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  1. Nigerian children in primary schools, aged 5-8 years
  2. Willing and able to consume the supplied servings of the study product/s or provided control pap
  3. Having written and oral informed consent from the parent/legal guardian and the participants gave oral and/or written assent.

Exclusion criteria

Exclusion Criteria:

  1. Children suffering from severe malnutrition and/or micronutrient deficiencies defined as (such children will be referred to a nearby health centre for appropriate treatment).

    1. Children with Height-for-age (HAZ) and Weight-for-age (WAZ) \<- 3 Standard Deviation (SD)
    2. Children showing clinical signs of severe (chronic) anemia i.e. visibly pale, jaundice and lethargic.
  2. Children with a history of or who at the time of recruitment suffer from chronic illness, including (but not limited to) renal diseases, thyroid disease, (metabolic) bone disease, genetic and/or congenital disorders e.g. Down syndrome and sickle cell anaemia, hepatic dysfunction, thalassemia or chronic diarrhea (e.g. irritable bowl syndrome). Based on medical history examination.
  3. Children with a physical disability or handicap that prevents participation in the study.
  4. Children with food allergies or intolerances.
  5. Children participating in any other clinical research (or having participated in any such study in the previous half year).
  6. Children or a child's family who are intending to withdraw from school or move out of the study region within the study period.
  7. Children consuming prescribed 'iron/folic acid, and (multi-)vitamin, and mineral supplements' during the course of the study within the last 2 months prior to the study as a minimum.
05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
934 participants (actual)

Study arms

  • Placebo comparator
    Low dose multiple micronutrient fortification

    Maize, milk plus low multiple micronutrient fortification

    Dietary Supplement: Multiple micronutrient fortified maize with milk

  • Active comparator
    Moderate dose multiple micronutrient fortification

    Maize, milk plus moderate multiple micronutrient fortification

    Dietary Supplement: Multiple micronutrient fortified maize with milk

  • Active comparator
    High dose multiple micronutrient fortification

    Maize, milk plus high multiple micronutrient fortification (double the moderate level)

    Dietary Supplement: Multiple micronutrient fortified maize with milk

Interventions

  • Dietary supplementMultiple micronutrient fortified maize with milk

    The study product is a multiple micronutrient fortified maize pap with milk

06

What researchers measure

Primary outcomes

  1. Iron status

    There will be a change between the two test groups and the control group in iron status as measured by in hemoglobin (whole blood) g/L .

    Time frame: 5 months

  2. Serum ferritin

    There will be a change between the two test groups and the control group in iron status as measured by serum ferritin (ug/L).

    Time frame: 5 months

Secondary outcomes

  1. Iron deficiency, iron deficiency anaemia and anemia

    There will be a difference in prevalence of iron-deficiency, iron-deficiency anaemia and anaemia, taking modifying factors like soluble transferrin receptor and inflammation markers in plasma into account.

    Time frame: 5 months

  2. Nutrient status

    A difference in nutrient status of selected nutrients (iodine, vitamin A, zinc, vitamin B12, vitamin D)

    Time frame: 5 months

Other outcomes

  1. Cognitive performance

    A difference in cognitive performance score, measured via attention (Digit span backward) and short-term memory (digit-span forward) score (higher scores indicate a better outcome.

    Time frame: 5 months

  2. Anthropometric scores

    Difference in anthropometric status between study arms as measured by height-for-age Z score (HAZ) and weight-for-age (WAZ).

    Time frame: 5 months

  3. Illness

    Difference in morbidity/illness as measured by the reduced frequency of illness over the 5 months

    Time frame: 5 months

07

Study locations

1 site
  • FrieslandCampina Research and Development
    Wageningen, 6708 WH, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06251427
Lead sponsor
FrieslandCampina
Collaborators
University of Ibadan
Responsible party
Sponsor
First posted
Feb 9, 2024
Start date
Jan 24, 2024
Primary completion
Aug 2, 2024
Completion
Aug 2, 2024
Last update
Jul 28, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion